@entity519 pelvic and limb perfusion with melphalan and @entity1138 for recurrent limb XXXX : a pilot study.

@entity1 @entity455 @entity137 @entity1138 @entity3601 @entity519 @entity204 @entity320
@entity519 pelvic and limb perfusion by means of a balloon occlusion technique was evaluated in @entity1 with recurrent @entity320 of the lower limbs who were non-responders to isolated hyperthermic limb perfusion or who were not eligible for this procedure. A pilot study was performed in 17 @entity1 , who underwent @entity519 pelvic and limb perfusion with 50 mg/m(2) of @entity3601 or 50 mg/m(2) of melphalan and 25 mg/m(2) of @entity1138 . Each procedure was followed by haemofiltration. A leakage monitoring study was performed in five of the 17 @entity1 . The response rate and time to disease progression were the primary endpoints, with overall survival as the secondary endpoint. During the procedures there were no technical, @entity455 , and no @entity204 occurred during surgery or in the postoperative period. Significant leakage (median 40%) was measured in the five @entity1 studied. No severe @entity137 was observed. After one course of treatment, the objective response rate was 47% (95% confidence interval 22.5-71.5%), the median time to disease progression was 10 months (range 2-40 months), and the 3 year overall survival was 20%. @entity519 pelvic and limb perfusion seems to be a safe and effective treatment for @entity1 with unresectable recurrent limb @entity320 who are not eligible for isolated hyperthermic limb perfusion. Due to the non-homogeneity of the study, with some @entity1 receiving a combination of melphalan and @entity1138 and others receiving only melphalan, it is not possible to make definite conclusions with regard to efficacy. Further studies are necessary to establish whether the response rates can be improved by using different drug regimens.
